Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis ; volume:50 ; number:4 ; year:2018 ; pages:1216-1229
Cellular physiology and biochemistry ; 50, Heft 4 (2018), 1216-1229
- Creator
-
Chen, Chia-Hui
Shyue, Song-Kun
Hsu, Chiao-Po
Lee, Tzong-Shyuan
- DOI
-
10.1159/000494573
- URN
-
urn:nbn:de:101:1-2018111423292962049833
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chen, Chia-Hui
- Shyue, Song-Kun
- Hsu, Chiao-Po
- Lee, Tzong-Shyuan
Other Objects (12)
Central retinal vein occlusion in a patient using the antipsychotic drug olanzapine: a case report
Atypical antipsychotic agents; Peas in a pod or chalk and cheese?
Unlocking treatment success: predicting atypical antipsychotic continuation in youth with mania
Olanzapine-induced mania
2-Bromoterguride–a potential atypical antipsychotic drug without metabolic effects in rats
Gender differences in the use of atypical antipsychotic medications for ICU delirium
The antipsychotic drugs olanzapine and haloperidol modify network connectivity and spontaneous activity of neural networks \(\textit in vitro}\)
Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone
Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
Synthesis and biological investigations of 3β-aminotropane arylamide derivatives with atypical antipsychotic profile
Metergoline Shares Properties with Atypical Antipsychotic Drugs Identified by Gene Expression Signature Screen
Central retinal vein occlusion in a patient using the antipsychotic drug olanzapine: a case report
Atypical antipsychotic agents; Peas in a pod or chalk and cheese?
Unlocking treatment success: predicting atypical antipsychotic continuation in youth with mania
Olanzapine-induced mania
2-Bromoterguride–a potential atypical antipsychotic drug without metabolic effects in rats
Gender differences in the use of atypical antipsychotic medications for ICU delirium
The antipsychotic drugs olanzapine and haloperidol modify network connectivity and spontaneous activity of neural networks \(\textit in vitro}\)
Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone
Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
Synthesis and biological investigations of 3β-aminotropane arylamide derivatives with atypical antipsychotic profile
Metergoline Shares Properties with Atypical Antipsychotic Drugs Identified by Gene Expression Signature Screen
Central retinal vein occlusion in a patient using the antipsychotic drug olanzapine: a case report
Atypical antipsychotic agents; Peas in a pod or chalk and cheese?
Unlocking treatment success: predicting atypical antipsychotic continuation in youth with mania
Olanzapine-induced mania
2-Bromoterguride–a potential atypical antipsychotic drug without metabolic effects in rats
Gender differences in the use of atypical antipsychotic medications for ICU delirium
The antipsychotic drugs olanzapine and haloperidol modify network connectivity and spontaneous activity of neural networks \(\textit in vitro}\)
Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone
Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
Synthesis and biological investigations of 3β-aminotropane arylamide derivatives with atypical antipsychotic profile